In vitro Antiviral Activity of Remdesivir Against SARS-CoV-2 and its Variants

Aleksandra Nowakowska; Hanul Choi; Kihoon Park; Jinha Kim; Yuyeon Jang; Jungmin Chun; Young Bong Kim; Hee-Jung Lee

doi:10.4167/jbv.2022.52.4.149

All Issue

2022 Vol.52, Issue 4 Preview Page Next Page

Original Article

In vitro Antiviral Activity of Remdesivir Against SARS-CoV-2 and its Variants

31 December 2022. pp. 149-159

PDF XML

Abstract

The outbreak of COVID-19 has become a public health emergency of international concern; thus, it is important to not only develop drugs for treating COVID-19 but also develop a method for evaluating the therapeutic effect based on the characteristics of SARS-CoV-2 and its variants. To test the antiviral activity of a drug against COVID-19, in this study, we established and compared experimental conditions, such as the treatment time and mode of action (dose) of the therapeutic substance, and a test method to evaluate its effectiveness. We optimized an assay for testing antiviral activity by plaque reduction, tissue culture infectious dose 50, and quantitative RT-PCR. These methods were applied to test the antiviral efficacy of the therapeutic against SARS-CoV-2. Antiviral activity testing using in vitro assays against SARS-CoV-2 and its variants was assessed by measuring plaque-reducing or cytopathic effects in Vero-E6 cells. The in vitro assay was validated by evaluating the antiviral activity of remdesivir. Remdesivir reduced SARS-CoV-2 titer without detectable cytotoxicity and successfully inhibited viral replication in a dose-dependent manner. Therefore, we suggest this in vitro assay as an effective method for testing the antiviral activity for a potential repurposed drug against COVID-19 or rapid screening of therapeutic candidates.

Keywords

SARS-CoV-2

Variant

Antiviral

Remdesivir

in vitro assay

References

The Lancet. COVID-19: the worst may be yet to come. Lancet 2020;396:71. 10.1016/S0140-6736(20)31517-832653057

Aleem A, Akbar Samad AB, Slenker AK. Emerging Variants of SARS-CoV-2 And Novel Therapeutics Against Coronavirus (COVID-19). Treasure Island: StatPearls, 2022.

Ahn DG, Shin HJ, Kim MH, Lee S, Kim HS, Myoung J, et al. Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19). J Microbiol Biotechnol 2020;30:313-24. 10.4014/jmb.2003.0301132238757

Zahradník J, Marciano S, Shemesh M, Zoler E, Harari D, Chiaravalli J, et al. SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution. Nat Microbiol 2021;6:1188-98. 10.1038/s41564-021-00954-434400835

Kandeel M, Mohamed MEM, Abd El-Lateef HM, Venugopala KN, El-Beltagi HS. Omicron variant genome evolution and phylogenetics. J Med Virol 2022;94:1627-32. 10.1002/jmv.2751534888894PMC9015349

Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, Evaluation, and Treatment of Coronavirus (COVID-19). Treasure Island: StatPearls, 2022.

Ku KB, Shin HJ, Kim HS, Kim BT, Kim SJ, Kim C. Repurposing Screens of FDA-Approved Drugs Identify 29 Inhibitors of SARS-CoV-2. J Microbiol Biotechnol 2020;30:1843-53. 10.4014/jmb.2009.0900933203821PMC9728307

Kim S. COVID-19 Drug Development. J Microbiol Biotechnol 2022;32:1-5. 10.4014/jmb.2110.10029PMC9628783

Singh M, de Wit E. Antiviral agents for the treatment of COVID-19: Progress and challenges. Cell Rep Med 2022;3:100549. 10.1016/j.xcrm.2022.10054935474740PMC8831133

Chan SW. Current and Future Direct-Acting Antivirals Against COVID-19. Front Microbiol 2020;11:587944. 10.3389/fmicb.2020.58794433262747PMC7688518

Griffin DO, Brennan-Rieder D, Ngo B, Kory P, Confalonieri M, Shapiro L, et al. The Importance of Understanding the Stages of COVID-19 in Treatment and Trials. AIDS Rev 2021;23:40-7. 10.24875/AIDSRev.20000126133556957

Suenaga R, Suka M, Hirao T, Hidaka I, Sakaida I, Ishida H. Cost-effectiveness of a "treat-all" strategy using Direct-Acting Antivirals (DAAs) for Japanese patients with chronic hepatitis C genotype 1 at different fibrosis stages. PLoS One 2021;16:e0248748. 10.1371/journal.pone.024874833793594PMC8016275

Vangeel L, Chiu W, De Jonghe S, Maes P, Slechten B, Raymenants J, et al. Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern. Antiviral Res 2022;198:105252. 10.1016/j.antiviral.2022.10525235085683PMC8785409

Wen W, Chen C, Tang J, Wang C, Zhou M, Cheng Y, et al. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19: a meta-analysis. Ann Med 2022;54:516-23. 10.1080/07853890.2022.203493635118917PMC8820829

Falcone M, Tiseo G, Valoriani B, Barbieri C, Occhineri S, Mazzetti P, et al. Efficacy of Bamlanivimab/Etesevimab and Casirivimab/Imdevimab in Preventing Progression to Severe COVID-19 and Role of Variants of Concern. Infect Dis Ther 2021;10:2479-88. 10.1007/s40121-021-00525-434435337PMC8386337

O'Horo J, Challener DW, Anderson RJ, Arndt RF, Ausman SE, Hall ST, et al. Rates of Severe Outcomes After Bamlanivimab-Etesevimab and Casirivimab-Imdevimab Treatment of High-Risk Patients With Mild to Moderate Coronavirus Disease 2019. Mayo Clin Proc 2022;97:943-50. 10.1016/j.mayocp.2022.02.00935512884PMC8864104

Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med 2021;384:693-704. 10.1056/NEJMoa202143632678530PMC7383595

Huang CW, Yu AS, Song H, Park JS, Wu SS, Khang VK, et al. Association Between Dexamethasone Treatment After Hospital Discharge for Patients With COVID-19 Infection and Rates of Hospital Readmission and Mortality. JAMA Netw Open 2022;5:e221455. 10.1001/jamanetworkopen.2022.145535258575PMC8905383

Rosas J, Liaño FP, Cantó ML, Barea JMC, Beser AR, Rabasa JTA, et al. Experience With the Use of Baricitinib and Tocilizumab Monotherapy or Combined, in Patients With Interstitial Pneumonia Secondary to Coronavirus COVID19: A Real-World Study. Reumatol Clin (Engl Ed) 2022;18:150-6. 10.1016/j.reuma.2020.10.009PMC7699160

Selvaraj V, Finn A, Lal A, Khan MS, Dapaah-Afriyie K, Carino GP. Baricitinib in hospitalised patients with COVID-19: A meta-analysis of randomised controlled trials. EClinicalMedicine 2022;49:101489. 10.1016/j.eclinm.2022.10148935677732PMC9163705

Coopersmith CM, Antonelli M, Bauer SR, Deutschman CS, Evans LE, Ferrer R, et al. The Surviving Sepsis Campaign: Research Priorities for Coronavirus Disease 2019 in Critical Illness. Crit Care Med 2021;49:598-622. 10.1097/CCM.000000000000489533591008

Vegivinti CTR, Evanson KW, Lyons H, Akosman I, Barrett A, Hardy N, et al. Efficacy of antiviral therapies for COVID-19: a systematic review of randomized controlled trials. BMC Infect Dis 2022;22:107. 10.1186/s12879-022-07068-035100985PMC8802260

Mostafa A, Kandeil A, A M M Elshaier Y, Kutkat O, Moatasim Y, Rashad AA, et al. FDA-Approved Drugs with Potent In Vitro Antiviral Activity against Severe Acute Respiratory Syndrome Coronavirus 2. Pharmaceuticals (Basel) 2020;13:443. 10.3390/ph1312044333291642PMC7761982

Simonis A, Theobald SJ, Fätkenheuer G, Rybniker J, Malin JJ. A comparative analysis of remdesivir and other repurposed antivirals against SARS-CoV-2. EMBO Mol Med 2021;13:e13105. 10.15252/emmm.202013105

Davies SP, Mycroft-West CJ, Pagani I, Hill HJ, Chen YH, Karlsson R, et al. The Hyperlipidaemic Drug Fenofibrate Significantly Reduces Infection by SARS-CoV-2 in Cell Culture Models. Front Pharmacol 2021;12:660490. 10.3389/fphar.2021.66049034421587PMC8377159

Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020;30:269-71. 10.1038/s41422-020-0282-032020029PMC7054408

Lei C, Yang J, Hu J, Sun X. On the Calculation of TCID50 for Quantitation of Virus Infectivity. Virol Sin 2021;36:141-4. 10.1007/s12250-020-00230-532458296PMC7973348

Park JG, Oladunni FS, Chiem K, Ye C, Pipenbrink M, Moran T, Walter MR, et al. Rapid in vitro assays for screening neutralizing antibodies and antivirals against SARS-CoV-2. J Virol Methods 2021;287:113995. 10.1016/j.jviromet.2020.11399533068703PMC7554492

Mendoza EJ, Manguiat K, Wood H, Drebot M. Two Detailed Plaque Assay Protocols for the Quantification of Infectious SARS-CoV-2. Curr Protoc Microbiol 2020;57:ecpmc105. 10.1002/cpmc.10532475066PMC7300432

Amanat F, White KM, Miorin L, Strohmeier S, McMahon M, Meade P, et al. An In Vitro Microneutralization Assay for SARS-CoV-2 Serology and Drug Screening. Curr Protoc Microbiol 2020;58:e108. 10.1002/cpmc.10832585083PMC7361222

Smither SJ, Lear-Rooney C, Biggins J, Pettitt J, Lever MS, Olinger GG Jr. Comparison of the plaque assay and 50% tissue culture infectious dose assay as methods for measuring filovirus infectivity. J Virol Methods 2013;193:565-71. 10.1016/j.jviromet.2013.05.01523748121

Amarilla AA, Modhiran N, Setoh YX, Peng NYG, Sng JDJ, Liang B, et al. An Optimized High-Throughput Immuno-Plaque Assay for SARS-CoV-2. Front Microbiol 2021;12:625136. 10.3389/fmicb.2021.62513633643253PMC7906992

Cresta D, Warren DC, Quirouette C Smith AP, Lane LC, Smith AM, et al. Time to revisit the endpoint dilution assay and to replace the TCID50 as a measure of a virus sample's infection concentration. PLoS Comput Biol 2021;17:e1009480. 10.1371/journal.pcbi.100948034662338PMC8553042

Gordon CJ, Tchesnokov EP, Woolner E, Perry JK, Feng JY, Porter DP, et al. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J Biol Chem 2020;295:6785-97. 10.1074/jbc.RA120.01367932284326PMC7242698

Frediansyah A, Nainu F, Dhama K, Mudatsir M, Harapan H. Remdesivir and its antiviral activity against COVID-19: A systematic review. Clin Epidemiol Glob Health 2021;9:123-7. 10.1016/j.cegh.2020.07.01132838064PMC7410793

Malin JJ, Suárez I, Priesner V, Fätkenheuer G, Rybniker J. Remdesivir against COVID-19 and Other Viral Diseases. Clin Microbiol Rev 2020;34-e00162-20. 10.1128/CMR.00162-2033055231PMC7566896

Pruijssers AJ, George AS, Schäfer A, Leist SR, Gralinksi LE, Dinnon KH 3rd, et al. Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice. Cell Rep 2020;32:107940. 10.1016/j.celrep.2020.10794032668216PMC7340027

Tripathi D, Sodani M, Gupta PK, Kulkarni S. Host directed therapies: COVID-19 and beyond. Curr Res Pharmacol Drug Discov 2021;2:100058. 10.1016/j.crphar.2021.10005834870156PMC8464038

Wei L, Adderley J, Leroy D, Drewry DH, Wilson DW, Kaushansky A, et al. Host-directed therapy, an untapped opportunity for antimalarial intervention. Cell Rep Med 2021;2:100423. 10.1016/j.xcrm.2021.10042334693368PMC8524702

Garcia G Jr, Sharma A, Ramaiah A, Sen C, Purkayastha A, Kohn DB, et al. Antiviral drug screen identifies DNA-damage response inhibitor as potent blocker of SARS-CoV-2 replication. Cell Rep 2021;35:108940. 10.1016/j.celrep.2021.10894033784499PMC7969873

Williamson BN, Feldmann F, Schwarz B, Meade-White K, Porter DP, Schulz J, et al. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. Nature 2020;585:273-6. 10.1038/s41586-020-2423-532516797PMC7486271

Information

Publisher :The Korean Society for Microbiology and The Korean Society of Virology
Publisher(Ko) :대한미생물학회‧대한바이러스학회
Journal Title :JOURNAL OF BACTERIOLOGY AND VIROLOGY
Volume : 52
No :4
Pages :149-159
Received Date : 2022-09-06
Revised Date : 2022-10-31
Accepted Date : 2022-11-01
DOI :https://doi.org/10.4167/jbv.2022.52.4.149

JOURNAL OF BACTERIOLOGY AND VIROLOGY ISSN:1598-2467(Print) 2093-0429(Online)

All Issue